L3VLUP
ProSign in

MRVI · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRVIJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRVI
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMRVIJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 202011 holders, $410m32 holders, $26.6bn
Q1 20214 holders, $230m31 holders, $25.3bn
Q2 20218 holders, $819m37 holders, $25.6bn
Q3 202110 holders, $1.4bn40 holders, $24.1bn
Q4 20216 holders, $900m33 holders, $25.2bn
Q1 20224 holders, $342m35 holders, $28.2bn
Q2 20224 holders, $447m33 holders, $26.9bn
Q3 20227 holders, $527m36 holders, $25.4bn
Q4 20228 holders, $360m35 holders, $27.6bn
Q1 20238 holders, $291m42 holders, $24.5bn
Q2 20237 holders, $234m38 holders, $25.0bn
Q3 20236 holders, $155m37 holders, $18.9bn
Q4 20233 holders, $73m31 holders, $19.0bn
Q1 20245 holders, $110m32 holders, $19.7bn
Q2 20246 holders, $91m35 holders, $20.4bn
Q3 20241 holders, $34m28 holders, $22.3bn
Q4 20241 holders, $251k37 holders, $20.4bn
Q1 2025none listed holders, n.a.32 holders, $20.5bn
Q2 2025none listed holders, n.a.31 holders, $18.4bn
Q3 20251 holders, $1.3m32 holders, $23.7bn
Q4 20251 holders, $5.8m29 holders, $27.8bn
Q1 20261 holders, $7.1m34 holders, $35.6bn
Q2 20262 holders, $24m33 holders, $39.1bn
MRVI

Maravai Lifesciences HLDGS I

Holders
5
Reported value
$110m
Buyers
2
Sellers
3

Breadth -1 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRVI (0)

None.

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC, Wellington Management Group LLP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →